CVM CEL SCI CORP
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 725363 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.9%
TTM EPS YoY81.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-252.5%
ROA-108.9%
ROIC (approx.)-364.5%
Asset turnover—
Leverage & solvency
Liabilities / assets48.7%
Debt / equity0.00x
Current ratio1.48x
Interest coverage-50.08x
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-28.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $15.89M | $18.16M | $22.47M | $25.36M | $23.11M |
| SG&A expense | $8.92M | $8.19M | $9.00M | $10.71M | $13.09M |
| Operating income | -$24.81M | -$26.35M | -$31.48M | -$36.06M | -$36.19M |
| Interest expense | $649,000 | $746,000 | $675,416 | $1.08M | — |
| Net income | -$25.41M | -$26.92M | -$32.37M | -$36.70M | -$36.36M |
| EBITDA | -$22.75M | -$24.22M | -$29.36M | -$34.09M | -$35.75M |
| EPS (basic) | — | — | — | -0.87 | -0.90 |
| EPS (diluted) | -6.27 | -15.31 | -0.73 | -0.87 | -0.90 |
| Weighted avg. shares (diluted) | 4.06M | 1.80M | 44.48M | 43.15M | 40.69M |
| Banking | |||||
| Net interest income | -$648,944 | -$745,673 | — | -$1.08M | -$1.15M |
| Balance sheet | |||||
| Cash & equivalents | $10.95M | $4.74M | $4.15M | $22.67M | $36.06M |
| Short-term investments | — | — | — | $0 | $6.15M |
| Receivables | — | — | — | $0 | $54,922 |
| Inventory | — | $1.02M | $2.25M | $2.00M | $2.01M |
| Current assets | $11.60M | $6.06M | $6.92M | $25.44M | $45.27M |
| PP&E, net | $6.08M | $8.13M | $10.19M | $11.89M | $13.66M |
| Intangibles | $119,856 | $165,492 | $197,704 | $212,201 | $275,866 |
| Total assets | $28.16M | $26.99M | $30.53M | $50.52M | $75.87M |
| Current liabilities | $5.13M | $4.62M | $5.59M | $4.66M | $3.94M |
| Short-term debt | $2.27M | — | — | — | — |
| Long-term debt | $5.68M | — | — | — | — |
| Total debt | $7.96M | — | — | — | — |
| Total liabilities | $12.20M | $14.12M | $17.31M | $18.36M | $19.34M |
| Shareholders' equity | $15.96M | $12.87M | $13.21M | $32.16M | $56.53M |
| Net debt | -$3.00M | — | — | — | — |
| Shares outstanding | 8.02M | 2.13M | 47.42M | 43.45M | 43.21M |
| Cash flow statement | |||||
| Operating cash flow | -$17.12M | -$18.81M | -$22.85M | -$18.24M | -$18.79M |
| Capital expenditure | $38,109 | $94,875 | $361,892 | $637,892 | $9.02M |
| Free cash flow | -$17.16M | -$18.91M | -$23.21M | -$18.88M | -$27.80M |
| Investing cash flow | -$38,109 | -$108,086 | -$372,262 | $5.49M | -$15.18M |
| Financing cash flow | $23.37M | $19.51M | $4.69M | -$638,426 | $54.52M |
| Depreciation & amortization | $2.06M | $2.13M | $2.11M | $1.98M | $447,000 |
| Stock-based compensation | $1.91M | $4.27M | $6.29M | $11.39M | $13.69M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.